Durability of clinical benefit with Stanford Neuromodulation Therapy (SNT) in treatment-resistant depression
At 12 weeks, a subset of participants remained in remission, suggesting that the durability of SNT warrants further study. Comparisons with conventional rTMS should be interpreted cautiously given differences in study design, populations, and outcome measures.
Authors
- Andrew Geoly (ORCID: https://orcid.org/0000-0002-3483-026X)
- Flint M. Espil (ORCID: https://orcid.org/0000-0003-4332-4358)
- Katy H. Stimpson (ORCID: https://orcid.org/0000-0001-5919-9673)
- Nolan Williams (ORCID: https://orcid.org/0000-0003-4368-3203)
- Brandon S. Bentzley (ORCID: https://orcid.org/0000-0001-6014-4514)
Institutions
- Stanford Medicine (US)
- Stanford University (US)
Publication Details
- Journal
- Brain stimulation
- Published
- 2025-04-08
- DOI
- https://doi.org/10.1016/j.brs.2025.04.006
- Citations
- 5
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 6.97
Funders
- Mellam Family Foundation